Pfizer has completed the acquisition of AstraZeneca’s late-stage small molecule anti-infectives business, gaining commercialization rights primarily outside the U.S. The agreement includes development and commercialization rights to the newly approved EU drug Zavicefta, marketed products Merrem/Meronem and Zinforo, and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. Zavicefta specifically addresses multi-drug resistant Gram-negative infections, including those resistant...